GlassScriptPhysician profile
Ryan S Drake
NPI 1326256462
$349,761.76
in general payments reported to CMS, 2019-2025
91 companies · $89K in 2025
The $89K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $53K · 2021: $44K · 2022: $49K · 2023: $19K · 2024: $63K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Travel and Lodging: $19K · Food and Beverage: $18K · Consulting Fee: $5,938 · Education: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $126,810.00 |
| Travel and Lodging | $19,255.07 |
| Food and Beverage | $17,835.88 |
| Consulting Fee | $5,937.50 |
| Education | $1,497.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $108,158.13 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $87,629.07 | 2019-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $57,339.29 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sk Life Science, INC. | $35,709.33 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $15,551.00 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $8,098.27 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Biohaven Pharmaceuticals, INC. | $7,736.01 | 2020-2021 | |
| Argenx US, INC. | $7,683.71 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $3,052.84 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Amneal Pharmaceuticals LLC | $1,436.84 | 2019-2025 | Ongentys, Rytary, Crexont |
| Amgen INC. | $1,308.50 | 2019-2025 | Aimovig, Uplizna |
| Emd Serono, INC. | $1,184.34 | 2019-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $1,094.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,084.00 | 2019-2025 | |
| Genzyme Corporation | $785.67 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $775.26 | 2019-2025 | |
| Lundbeck LLC | $733.81 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $684.75 | 2019-2025 | |
| Harmony Biosciences LLC | $633.72 | 2020-2025 | Wakix |
| Tg Therapeutics, INC. | $632.54 | 2023-2025 | |
| Genentech USA, INC. | $627.27 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $589.45 | 2019-2025 | Nuplazid, Daybue |
| Biogen, INC. | $475.83 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Celgene Corporation | $474.32 | 2021-2024 | Zeposia |
| Kyowa Kirin, INC. | $423.55 | 2019-2024 | Nourianz |
| Allergan, INC. | $325.12 | 2020-2022 | |
| Axsome Therapeutics, INC. | $306.10 | 2023-2025 | Sunosi, Symbravo |
| Janssen Pharmaceuticals, INC | $302.89 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $293.12 | 2019-2025 | Ponvory |
| Janssen Biotech, INC. | $279.63 | 2025 | |
| Sunovion Pharmaceuticals INC. | $271.38 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $240.78 | 2021-2025 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $238.59 | 2023-2025 | Lumryz |
| Biohaven Pharmaceutical Holding Company LTD. | $228.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.69 | 2023-2025 | Hyqvia, Gammagard |
| Neurelis, INC. | $209.66 | 2020-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $190.84 | 2020 | |
| Horizon Therapeutics Plc | $164.56 | 2021-2023 | Uplizna |
| Sumitomo Pharma America, INC. | $137.60 | 2023 | Aptiom, Latuda |
| Avion Pharmaceuticals | $123.06 | 2022-2023 | Dhivy |
| Avanir Pharmaceuticals, INC. | $117.55 | 2019-2022 | |
| Acorda Therapeutics, INC | $111.02 | 2019-2024 | Inbrija, Ampyra |
| Grifols USA, LLC | $108.64 | 2023-2025 | Gamunex-C |
| Neuropace, INC. | $102.51 | 2022 | |
| Tanabe Pharma America, INC. | $101.32 | 2019-2025 | Radicava |
| Upsher-Smith Laboratories LLC | $101.01 | 2019-2021 | |
| Ge Healthcare | $98.75 | 2019-2025 | |
| C2n Diagnostics, LLC | $90.17 | 2025 | Precivityad2 |
| Alnylam Pharmaceuticals INC. | $86.00 | 2024-2025 | Onpattro, Amvuttra |
| Supernus Pharmaceuticals, INC. | $85.43 | 2020-2022 | |
| Corium, LLC | $84.25 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $79.84 | 2025 | Wainua |
| Catalyst Pharmaceuticals, INC. | $75.58 | 2023-2025 | Firdapse |
| Impel Pharmaceuticals INC. | $68.17 | 2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $67.90 | 2019-2023 | Ztlido |
| Neos Therapeutics, LP | $65.74 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $64.16 | 2024-2025 | Rexulti, Nuedexta |
| Impel Pharmaceuticals LLC | $63.06 | 2024-2025 | Trudhesa |
| Strongbridge US INC. | $62.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.55 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $55.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $53.12 | 2020-2021 | |
| Aucta Pharmaceuticals, INC. | $46.62 | 2024 | Motpoly Xr |
| Greenwich Biosciences, INC. | $46.29 | 2019-2021 | |
| Inspire Medical Systems, INC. | $45.50 | 2023 | Inspire |
| Nevro Corp. | $33.97 | 2023 | Senza |
| Cycle Pharmaceuticals INC | $33.77 | 2025 | Tascenso Odt, Bafiertam |
| Bausch Health US, LLC | $33.52 | 2019 | |
| Collegium Pharmaceutical, INC. | $27.70 | 2022 | |
| Vertical Pharmaceuticals, LLC | $27.55 | 2019 | |
| Mdd US Operations, LLC | $24.18 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.87 | 2025 | Rexulti |
| Flowonix Medical Incorporated | $20.27 | 2019 | |
| Csl Behring | $19.16 | 2019 | |
| Itamar Medical INC | $16.52 | 2024 | Watchpatone |
| Livanova USA, INC. | $16.47 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ipsen Biopharmaceuticals, INC | $14.32 | 2024 | Dysport |
| Springworks Therapeutics, INC. | $14.07 | 2025 | Gomekli |
| Assertio Therapeutics, INC. | $13.78 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $13.75 | 2024 | Relyvrio |
| Cala Health, INC. | $13.59 | 2023 | Cala Trio |
| Abbott Laboratories | $13.28 | 2022 | |
| Merz Pharmaceuticals, LLC | $13.10 | 2024 | Inbrija, Xeomin |
| Advanced Respiratory, INC | $11.14 | 2020 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$74,841.65 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.